We estimate the device will be available by 2026. As the device will be a medical device regulated by medical device regulations this takes time to develop and validate. In addition there is the time required to have the product tested by independent testing houses to ensure that the device is safe and compliant with the standards

Our research suggests that the stimulation is suitable for anyone over 12 years of age.

The UK-wide double-blind sham-controlled clinical trial of the Neupulse device for suppressing tics in Tourette syndrome run by the University of Nottingham showed that:

People who received active stimulation experienced a significant reduction in the severity and frequency of their tics. On average, they saw a reduction in tic frequency of more than 25% while they received stimulation.

After using the device for 4 weeks, people who received active stimulation experienced a reduction in their tic severity of more than 35%. In total, 59% of the people who received active stimulation experienced a reduction in tic severity of at least 25% compared to baseline.

The clinical trial investigating the effects of median nerve stimulation on Tourette syndrome and associated symptoms has completed recruitment and no more volunteers are required.

Unfortunately No. Our research investigating the use of median nerve stimulation to reduce tics in Tourette syndrome is a novel approach and there is currently no other clinical trials or similar research going on outside of the UK.

Most definitely. Our research team at the University of Nottingham is continuously conducting research aimed at understanding brain health conditions like Tourette syndrome and developing new treatment approaches. If you would like to volunteer to take part in these research studies, please take a look at the following link:

https://tsresearchuon.wixsite.com/jackson-lab